These results may provide an important indication that clinicians should consider a re-biopsy of specimens to assess the phenotype of SPARC for previously treated GC patients scheduled for taxanes-based chemotherapy, especially for nab-paclitaxel. This evidence concerns the gene SPARC and gastric cancer.